MedPath
Found 119 clinical trials|View Analysis
Sort by:

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

Phase 2
Recruiting
Conditions
Severe Aplastic Anemia
Cyclophosphamide Reduced-dose
Immunosuppressive Therapy
Interventions
First Posted Date
2024-11-19
Last Posted Date
2024-11-19
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
75
Registration Number
NCT06695741
Locations
🇨🇳

Red Blood Cell Disorders Center and Regenerative Medicine Center, Tianjin, Tianjin, China

CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia

Early Phase 1
Recruiting
Conditions
Aplastic Anemia
Interventions
Drug: CD7 CAR-T cells injection
Other: Allogeneic hematopoietic stem cell transplantation
First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Zhejiang University
Target Recruit Count
30
Registration Number
NCT06633328
Locations
🇨🇳

The First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang, China

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

Phase 1
Not yet recruiting
Conditions
Severe Aplastic Anemia
Relapse
Refractory
CAR T-cell Therapy
Interventions
Biological: RD13-02
First Posted Date
2024-10-02
Last Posted Date
2024-10-02
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
15
Registration Number
NCT06622694
Locations
🇨🇳

Regenerative Medicine Clinic Center, Tianjin, Tianjin, China

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

Phase 2
Recruiting
Conditions
Aplastic Anemia
TPO Receptor Agonists
Interventions
Drug: standard IST combined with Romiplostim N01
First Posted Date
2024-09-26
Last Posted Date
2024-12-04
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
48
Registration Number
NCT06613880
Locations
🇨🇳

Regenerative Medicine Center and Red Blood Cell Disorders Center, Tianjin, Tianjin, China

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

Phase 2
Not yet recruiting
Conditions
Severe Aplastic Anemia
Interventions
Drug: Haploidentical donor bone marrow transplant
Drug: Unrelated donor bone marrow transplant
First Posted Date
2024-07-24
Last Posted Date
2024-07-24
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
60
Registration Number
NCT06517641
Locations
🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Stanford University, Stanford, California, United States

and more 7 locations

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Phase 2
Recruiting
Conditions
Acquired Amegakaryocytic Thrombocytopenia
Acquired Pure Red Cell Aplasia
Severe Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Drug: Rituximab
Drug: Rabbit ATG
Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total Body Irradiation
Biological: Cell Infusion
Drug: Post-Transplant G-CSF
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
First Posted Date
2024-05-14
Last Posted Date
2024-06-10
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
60
Registration Number
NCT06412497
Locations
🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

Phase 2
Recruiting
Conditions
Severe Aplastic Anemia
Interventions
Drug: Modified transplantation system
First Posted Date
2024-04-22
Last Posted Date
2024-04-22
Lead Sponsor
Hematology department of the 920th hospital
Target Recruit Count
30
Registration Number
NCT06378060
Locations
🇨🇳

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan, China

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Phase 1
Not yet recruiting
Conditions
Myelodysplastic Syndromes
Acute Leukemia
Severe Aplastic Anemia
Interventions
First Posted Date
2024-02-28
Last Posted Date
2024-03-21
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
6
Registration Number
NCT06279494

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Phase 2
Recruiting
Conditions
Severe Aplastic Anemia
Platelet Transfusion Refractoriness
Interventions
First Posted Date
2024-02-12
Last Posted Date
2024-02-12
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
20
Registration Number
NCT06254560
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA

Phase 4
Recruiting
Conditions
Severe Aplastic Anemia
Interventions
Drug: Flu/Cy/ATG or Cy/ATG
Drug: Busulfan
First Posted Date
2023-10-05
Last Posted Date
2023-11-18
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
160
Registration Number
NCT06069180
Locations
🇨🇳

Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath